Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dana-Farber Cancer Institute (DFCI) Wu Lab/Avicenne CLL RNA-seq Study

ABSTRACT: Dana-Farber Cancer Institute (DFCI) Wu Lab/Avicenne CLL RNA-seq Study

PROVIDER: PRJNA695804 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Dana-Farber Cancer Institute (DFCI) Wu Lab/Avicenne CLL RNA-seq Study

Project description:Dana-Farber Cancer Institute (DFCI) Wu Lab/Avicenne CLL RNA-seq Study

| PRJNA695805 | ENA

RNA-seq expression analysis of patient-derived xenografts in NSG mice--Dana-Farber Cancer Institute blood cancers

Project description:RNA-seq expression analysis of patient-derived xenografts in NSG mice--Dana-Farber Cancer Institute blood cancers

| PRJEB38661 | ENA

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Trials Network Site (DF/HCC ETCTN Site) Trial 10057

Project description:Dana-Farber/Harvard Cancer Center Experimental Therapeutics Trials Network Site (DF/HCC ETCTN Site) Trial 10057

| PRJNA1069855 | ENA

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Trials Network Site (DF/HCC ETCTN Site) 9825, 9875, and 9984 Analyses

Project description:Dana-Farber/Harvard Cancer Center Experimental Therapeutics Trials Network Site (DF/HCC ETCTN Site) 9825, 9875, and 9984 Analyses

| PRJNA1068762 | ENA

Expression profiling of acute megakaryoblastic leukemia

Project description:mononuclear cells were isolated on a density gradient and RNA extracted using Trizol and the Promega SV column RNA purification. Affymetrix U133A chips were hybridised using standard procedures at the core facility of Dana Farber Cancer Institute. Keywords: disease state analysis

2006-03-16 | GSE4119 | GEO

RNA-seq expression analysis of patient-derived xenografts in NSG mice--Dana-Farber Cancer Institute blood cancers

Project description:To provide a snapshot of gene expression for the cancer models distributed by The Jackson Laboratory.

2021-12-17 | E-MTAB-9176 | biostudies-arrayexpress

WU Polyomavirus

Project description:WU Polyomavirus Genome sequencing and assembly

| PRJNA663189 | ENA

WU Polyomavirus

Project description:WU Polyomavirus Genome sequencing and assembly

| PRJNA663191 | ENA

An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001.

Project description:PurposeThis study compared the relative incidence of treatment-related toxicities and the event-free and overall survival between Hispanic and non-Hispanic children undergoing therapy for acute lymphoblastic leukemia (ALL) on Dana-Farber Cancer Institute ALL Consortium protocol 05-001.Patients and methodsSecondary analysis of prospectively collected data from a phase III multicenter study in children and adolescents of 1-18 years with previously untreated ALL.ResultsBetween 2005 and 2011, 794 eligible patients enrolled on DFCI 05-001, 730 of whom were included in this analysis (19% [N = 150] Hispanic, 73% [N = 580] non-Hispanic). Hispanic patients were more likely to be ≥10 years of age (32% vs. 24%, P = 0.045) at diagnosis. Toxicity analyses revealed that Hispanic patients had significantly lower cumulative incidence of bone fracture (P < 0.001) and osteonecrosis (ON; P = 0.047). In multivariable risk regression, the risk of ON was significantly lower in Hispanic patients ≥10 years (HR 0.23; P = 0.006). Hispanic patients had significantly lower 5-year event-free survival (EFS) (79.4%; 95% CI: 71.6-85.2) and overall survival (OS) (89.2%; 95% CI: 82.7-93.4) than non-Hispanic patients (EFS: 87.5%; 95% CI: 84.5-90.0, P = 0.004; OS: 92.7%; 95% CI: 90.2-94.6, P = 0.006). Exploratory analyses revealed differences between Hispanic and non-Hispanic patients in the frequency of common variants in genes related to toxicity or ALL outcome.ConclusionHispanic children treated for ALL on DFCI 05-001 had fewer bone-related toxicities and inferior survival than non-Hispanic patients. While disease biology is one explanatory variable for outcome disparities, these findings suggest that biologic and non-biologic mechanisms affecting drug delivery and exposure in this population may be important contributing factors as well.

| S-EPMC5766393 | biostudies-literature

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.

Project description:BackgroundDexrazoxane reduces the risk of anthracycline-related cardiotoxicity. In a study of children with Hodgkin lymphoma, the addition of dexrazoxane may have been associated with a higher risk for developing second malignant neoplasms (SMNs) including acute myelogenous leukaemia (AML) and myelodysplastic syndrome (MDS). We determined the incidence of SMNs in children and adolescents with acute lymphoblastic leukaemia (ALL) who were treated with dexrazoxane.MethodsBetween 1996 and 2010, the Dana-Faber Cancer Institute ALL Consortium conducted three consecutive multicentre trials for children with newly diagnosed ALL. In the first (1996-2000), high risk patients were randomly assigned to receive doxorubicin (30mg/m(2)/dose, cumulative dose 300mg/m(2)) preceded by dexrazoxane (300mg/m(2)/dose, 10 doses), or the same dose of doxorubicin without dexrazoxane, during induction and intensification phases. In subsequent trials (2000-2005 and 2005-2010), all high risk and very high risk patients received doxorubicin preceded by dexrazoxane. Cases of SMNs were collected prospectively and were pooled for analysis. The frequency and 5-year cumulative incidence (CI) of SMNs were determined for patients who had received dexrazoxane.FindingsAmong 553 patients treated with dexrazoxane (1996-2000, N=101; 2000-2005, N=196; and 2005-2010, N=256), the number of SMNs observed by protocol was 0 (median follow-up 9.6years), 0 (median follow-up 5.2years), and 1 (median follow-up 2.1years). The only SMN was a case of AML, which developed in a patient with MLL-rearranged ALL 2.14years after initial diagnosis. The overall 5-year CI of SMNs for all 553 patients was 0.24±0.24%.InterpretationIn a large population of children with high risk ALL who received dexrazoxane as a cardioprotectant drug, the occurrence of secondary AML was a rare event.

| S-EPMC3736806 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data